Company news

Cumberland Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

March 4, 2024

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 6, 2023

Cumberland Pharmaceuticals to announce third quarter 2023 financial results

October 30, 2023

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

August 7, 2023

Cumberland Pharmaceuticals to announce second quarter 2023 financial results

July 31, 2023

Cumberland Pharmaceuticals announces FDA clearance of IND for new treatment of idiopathic pulmonary fibrosis

May 22, 2023

Caldolor® now FDA approved for treatment of fever & pain in infants

May 14, 2023

Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update

May 8, 2023

Cumberland Pharmaceuticals to announce first quarter 2023 financial results

May 1, 2023

Cumberland Pharmaceuticals reports 17% revenue growth for full year 2022

March 6, 2023

Cumberland Pharmaceuticals to announce annual 2022 financial results

February 27, 2023

Cumberland Pharmaceuticals Reports 41% Revenue Growth

November 7, 2022

Cumberland Pharmaceuticals moves into new headquarters at Broadwest

October 31, 2022

Cumberland Pharmaceuticals Reports 14% Revenue Growth

August 8, 2022

Cumberland Pharmaceuticals reports 2.4M patient doses delivered, no product recalls, no FDA issues in 2021

August 7, 2022

Cumberland Pharmaceuticals to announce second quarter 2022 financial results

August 1, 2022

Cumberland Pharmaceuticals appoints martin brown jr. to its board of directors

July 18, 2022

Cumberland Pharmaceuticals Reports 6% Revenue Growth

May 9, 2022

Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®

May 8, 2022

Cumberland Pharmaceuticals to announce first quarter 2022 financial results

May 2, 2022

Cumberland Pharmaceuticals reports 2021 financial results & company update

March 7, 2022

Cumberland Pharmaceuticals to announce annual 2021 financial results

February 28, 2022

Cumberland Pharmaceuticals acquires SANCUSO® from Kyowa Kirin north america

January 3, 2022

Caldolor® Now FDA Approved For Pre-Operative Administration

November 28, 2021

Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update

November 8, 2021

Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis

September 28, 2021

Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update

August 9, 2021

Cumberland Pharmaceuticals To Announce Second Quarter 2021 Financial Results

August 2, 2021

Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020

July 25, 2021

Cumberland Pharmaceuticals Names John Hamm New Chief Financial Officer

May 18, 2021

Cumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update

May 10, 2021

Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020

March 8, 2021

Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results

March 1, 2021

Introducing RediTrex®, A New Methotrexate Delivery System

November 16, 2020

Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update

November 9, 2020

Cumberland Pharmaceuticals To Announce Third Quarter 2020 Financial Results

November 2, 2020

Cumberland Pharmaceuticals Reports Second Quarter 2020 Financial Results & Company Update

August 10, 2020

Caldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients

July 19, 2020

Cumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update

May 19, 2020

Cumberland Pharmaceuticals Releases Inaugural Report On Its Environmental, Social And Governance (ESG) Activities

April 27, 2020

To Help Prepare for the COVID-19 Patient Surge Cumberland Pharmaceuticals Expands Availability of Vaprisol® to Treat Hyponatremia in Critical Care Units

April 6, 2020

Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor® to Help Treat High Fevers Associated With Coronavirus Infections

March 30, 2020

Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections

March 22, 2020

Cumberland Pharmaceuticals Reports 17% Revenue Growth For The Full Year 2019

March 17, 2020

Cumberland Pharmaceuticals Reschedules Fourth Quarter And Annual 2019 Financial Results

March 5, 2020

Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product

January 6, 2020

Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line

December 1, 2019

Cumberland Pharmaceuticals Reports 22% Revenue Growth In The Third Quarter

November 11, 2019

Cumberland Pharmaceuticals To Announce Third Quarter 2019 Financial Results

November 4, 2019

Cumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program

September 23, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.